Comparing the current results to its competitors, Fulgent Genetics Inc reported Revenue decrease in the 1 quarter 2026 year on year by -3.89 %, despite the revenue increase by the most of its competitors of 10.97 %, recorded in the same quarter.
Fulgent Genetics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 30.56 %
Fulgent Genetics Inc 's Comment on Competition and Industry Peers
The company competes in genetic and diagnostic testing with Laboratory Corporation of America Holdings, Natera, Inc., Myriad Genetics, Inc., Quest Diagnostics Incorporated, and other commercial and academic laboratories. Some competitors aligned with key suppliers may have significant advantages. Hospitals, research institutions, and individual practitioners also perform similar testing in-house due to decreasing equipment and material costs. In cancer therapeutics, competitors include drug delivery platform companies, 505(b)(2) drug developers, nano drug manufacturers such as Bristol-Myers Squibb, academic research institutions, government agencies, and other public and private research organizations. Many competitors have longer histories, larger customer bases, greater brand recognition, and more extensive resources.
July 17, 2025
In an exciting development for Fulgent Genetics, Inc. (NASDAQ: FLGT), the company has received CE certification under the European Union s In Vitro Diagnostic Regulation (EU IVDR) 2017/746 for its germline next-generation sequencing (NGS) system, including the FulgentExome and Fulgent Pipeline Manager (PLM). This move signifies a promising new chapter for the company as it positions its cutting-edge technology within the European market, promising to enhance its competitive edge in the global genetic testing landscape. Yet, alongside this regulatory accomplishment, Fulgent faces multifaceted challenges as it navigates its financial trajectory and market presence in a fluctuating economic climate. Strategic A...
October 31, 2024
Fulgent Genetics Secures Five-Year Contract with U.S. Department of Veterans Affairs for Genetic Testing Services In a significant move to enhance healthcare services for American veterans, Fulgent Genetics, Inc. (NASDAQ: FLGT), a prominent player in technology-driven laboratory services and therapeutic development, has been awarded a five-year contract by the U.S. Department of Veterans Affairs (VA). Under this agreement, Fulgent will provide a comprehensive array of genetic testing services, including hereditary cancer assessments, pharmacogenetic testing, and other genetic diagnostic services tailored specifically for veterans.Fulgent Genetics has established itself as a leader in clinical molecular diagn...
Caredx Inc is a precision medicine company with a business model focused on transplant diagnostics. They develop and commercialize non-invasive tests to identify and monitor organ transplant rejection. By offering innovative solutions and services in the transplant field, Caredx Inc aims to improve outcomes for patients and provide healthcare professionals with valuable information to guide treatment decisions.
Guardant Health Inc's business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.
iSpecimen Inc's business model revolves around connecting researchers with the biospecimens they need for their scientific and medical studies. They serve as an intermediary platform that links healthcare organizations and biobanks to the research community, providing a streamlined process for sourcing human biosamples and associated data.
Sources:
Fulgent Genetics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Fulgent Genetics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
